• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
New Products
You are here: Home > New Products
Toolbar - View Selection
 
 Items 1-20 of 155 Page 1 of 8 Select Page: 1 2 3 4 5 6 7 8  >>  
ALX-350-275 Revised 04-Aug-08 New product
Jasplakinolide
Add to Clipboard
SYNONYMS Jaspamide
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products for Cytoskeletal Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-275-C050   50 µg 150.00 USD Add To Cart
ALX-350-275-C100   100 µg 250.00 USD Add To Cart
Product Specification
FORMULA: C36H45BrN4O6
MW: 709.7
CAS NUMBER: 102396-24-7
SOURCE/HOST: Isolated from Jaspis splendens.
PURITY: ≥97% (HPLC)
APPEARANCE: Off-white to yellow solid.
SOLUBILITY: Soluble in 100% ethanol, 83% methanol or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: HARMFUL.
IDENTITY: Identity determined by MS.

Product Description
Cell permeable F-actin probe. Induces actin polymerization. Completely inhibits the binding of phalloidin to F-actin. Antifungal and anti-proliferative agent.
Product Specific Literature References
New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species: V.R. Scott, et al.; Antimicrob. Agents Chemother. 32, 1154 (1988) Abstract
In vitro screening of crude extracts and pure metabolites obtained from marine invertebrates for the treatment of breast cancer: J. Stingl, et al.; Cancer Chemother. Pharmacol. 30, 401 (1992) Abstract
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin: M.R. Bubb, et al.; J. Biol. Chem. 269, 14869 (1994) Abstract; Full Text
Growth modulation and differentiation of acute myeloid leukemia cells by jaspamide: I. Fabian, et al.; Exp. Hematol. 23, 583 (1995) Abstract
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton: A.M. Senderowicz, et al.; J. Natl. Cancer Inst. 87, 46 (1995) Abstract
Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma: H. Takeuchi, et al.; Cancer Chemother. Pharmacol. 42, 491 (1998) Abstract
Role of actin-filament disassembly in lamellipodium protrusion in motile cells revealed using the drug jasplakinolide: L.P. Cramer; Curr. Biol. 9, 1095 (1999) Abstract
Actin stabilization by jasplakinolide enhances apoptosis induced by cytokine deprivation: S.C. Posey & B.E. Bierer; J. Biol. Chem. 274, 4259 (1999) Abstract; Full Text
The anti-proliferative agent jasplakinolide rearranges the actin cytoskeleton of plant cells: H. Sawitzky, et al.; Eur. J. Cell Biol. 78, 424 (1999) Abstract
Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations: M.R. Bubb, et al.;; J. Biol. Chem. 275, 5163 (2000) Abstract; Full Text
A role for the actin cytoskeleton in the initiation and maintenance of store-mediated calcium entry in human platelets. Evidence for conformational coupling: J.A. Rosado, et al.; J. Biol. Chem. 275, 7527 (2000) Abstract; Full Text
A simple model for the cooperative stabilisation of actin filaments by phalloidin and jasplakinolide: B. Visegrády, et al.; FEBS Lett. 579, 6 (2005) Abstract
Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide: F. Lázaro-Diéguez, et al.; J. Cell Sci. 121, 1415 (2008) Abstract
Further Categories Containing This Product:
Actin/Related Products
 
 
ALX-420-045 Revised 19-Aug-08 New product
Purmorphamine
Add to Clipboard
SYNONYMS 2-(1-Naphthoxy)-6-(4-morpholinoanilino)-9-cyclohexylpurine
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Hedgehog [Hh] Signalling Pathway
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-420-045-M001   1 mg 40.00 USD Add To Cart
ALX-420-045-M005   5 mg 145.00 USD Add To Cart
ALX-420-045-M025   25 mg 510.00 USD Add To Cart
Product Specification
FORMULA: C31H32N6O2
MW: 520.6
CAS NUMBER: 483367-10-8
PURITY: ≥98% (HPLC)
APPEARANCE: Beige solid.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Packaged under inert gas. Protect from light.
HAZARD: HARMFUL. MAY BE CARCINOGENIC. MAY BE TERATOGENIC.

Product Description
Cell permeable purine compound. Induces osteoblast differentiation. Agonist of smoothened by activation of the hedgehog pathway. Also shown to induce transdifferentiation in pre-adipocytes and myoblasts.
Product Specific Literature References
A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells: X. Wu, et al.; JACS 124, 14520 (2002) Abstract
Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway: X. Wu, et al.; Chem. Biol. 11, 1229 (2004) Abstract
Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells: M.M. Beloti, et al.; Cell Biol. Int. 29, 537 (2005) Abstract
Purmorphamine activates the Hedgehog pathway by targeting Smoothened: S. Sinha & J.K. Chen; Nat. Chem. Biol. 2, 29 (2006) Abstract
Further Categories Containing This Product:
Cell Differentiation
 
 
ALX-350-162 Revised 11-Aug-08 New product
Altersolanol A
Add to Clipboard
SYNONYMS As-A 2
NSC 173943
(1R-(1α,2β,3β,4α))-1,2,3,4-Tetrahydro-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-9,10-anthracenedione
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products with Antibiotic Activity
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-162-M001   1 mg 120.00 USD Add To Cart
Product Specification
FORMULA: C16H16O8
MW: 336.3
CAS NUMBER: 22268-16-2
SOURCE/HOST: Isolated from Alternaria sp.
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow-orange to brown solid.
SOLUBILITY: Soluble in DMSO or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
IDENTITY: Identity determined by 1H-NMR and MS.

Product Description
Tetrahydroanthraquinone with phytotoxic and antibacterial activity.
Product Specific Literature References
Metabolites of Dactylaria lutea. The structures of dactylariol and the antiprotozoal antibiotic dactylarin: A.M. Becker, et al.; J. Antibiot. (Tokyo) 31, 324 (1978) Abstract
High-performance liquid chromatographic determination of macrosporin, altersolanol A, alterporriol A, B and C in fermentation of Alternaria porri (Ellis) Ciferri: R. Suemitsu, et al.; J. Chromatogr. 454, 406 (1988) Abstract
Mode of phytotoxic action of altersolanols : H. Haraguchi, et al.; Phytochemistry 43, 989 (1996)
Biologically active polyketide metabolites from an undetermined fungicolous hyphomycete resembling Cladosporium: U. Höller, et al.; J. Nat. Prod. 54, 876 (2002) Abstract
Secondary metabolite profiling of Alternaria dauci, A. porri, A. solani, and A. tomatophila: B. Andersen, et al.; Mycol. Res. 112, 241 (2008) Abstract
 
 
ALX-270-482 Revised 23-Apr-08 New product
GANT61
Add to Clipboard
SYNONYMS NSC 136476
2,2’-[[Dihydro-2-(4-pyridinyl)-1,3(2H,4H)-pyrimidinediyl]bis(methylene)]bis[N,N-dimethyl]-benzenamine
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Hedgehog [Hh] Signalling Pathway
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-482-M001   1 mg 190.00 USD Add To Cart
Product Specification
FORMULA: C27H35N5
MW: 429.6
CAS NUMBER: 500579-04-4
PURITY: ≥95%
APPEARANCE: White to off-white waxy solid.
SOLUBILITY: Soluble in DMSO (5mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Hygroscopic. Protect from light.
IDENTITY: Identity determined by 1H-NMR, 13C-NMR and MS.

Product Description
Inhibitor of Hedgehog (Hh) signalling pathway. Blocks the GLI function which constitutes the final step in the Hh pathway. Interferes with GLI1 DNA binding in living cells. Inhibits cell proliferation of tumor cells in vitro in a GLI-dependent manner. Blocks cell growth in an in vivo xenograft model using human prostate cancer cells.
Product Specific Literature References
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists: M. Lauth, et al.; PNAS 104, 8455 (2007) Abstract; Full Text
Further Categories Containing This Product:
Antitumor Reagents Other Products
 
 
ALX-350-371 Revised 10-Mar-08 New product
Harmine
Add to Clipboard
SYNONYMS Leucoharmine
Banisterine
Telepathine
Yageine
7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Other Natural Products - DNA Regulation/Transcription
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-371-M250   250 mg 22.00 USD Add To Cart
Product Specification
FORMULA: C13H12N2O
MW: 212.3
CAS NUMBER: 442-51-3
MERCK INDEX: 14: 4616
RTECS: UV0175000
SOURCE/HOST: Originally isolated from Peganum harmala.
PURITY: ≥98%
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO, dimethyl formamide or 100% ethanol; slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: HARMFUL.

Product Description
Alkaloid of the β-carboline family. Regulates PPARγ expression. Inhibits the Wnt signalling pathway in a cell-specific manner. Down-regulates inflammatory gene expression (TNF-α, IL-1β, iNOS). Reversibly inhibits monoamine oxidase inhibitor A (MAO-A), but has no effect on MAO-B.
Product Specific Literature References
The chemotherapy of derivatives of harmine and harmaline. I: C.E. Coulthard, et al.; Biochee. J. 27, 727 (1933) Abstract; Full Text
The chemotherapy of derivatives of harmine and harmaline. II: C.E. Coulthard; Biochem. J. 28, 264 (1934) Abstract; Full Text
Interrelationships between amphetamine and harmala alkaloids: H. Schmitt; Nature 203, 877 (1964) Abstract
Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline: J. Gerardy; Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 793 (1994) Abstract
Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism: A.F. Abdel-Fattah, et al.; Pharmacol. Biochem. Behav. 52, 421 (1995) Abstract
The mode of action of thiazolidinediones: H. Hauner; Diabet. Metab. Res. Rev. 18, S10 (2002) Abstract
Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis: Q. Chen, et al.; Int. J. Cancer 114, 675 (2005) Abstract
The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression: H. Waki, et al.; Cell Metab. 5, 357 (2007) Abstract
Further Categories Containing This Product:
Natural Products - Other Signal Transduction Pathway Modulators • Antidiabetic Agents/Related Products • Interleukin-1 [IL-1] & Receptors/Related Products • Wnt Signalling Pathway Other Products • TNF-alpha & TNF Receptors Other Products • NOS Regulation • Alkaloids
 
 
ALX-270-480 Revised 10-Mar-08 New product
Caffeic acid ethyl ester
Add to Clipboard
SYNONYMS CAEE
Ethyl caffeate
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Anti-inflammatory Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-480-M050   50 mg 20.00 USD Add To Cart
ALX-270-480-M250   250 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C11H12O4
MW: 208.2
CAS NUMBER: 66648-50-8
SOURCE/HOST: Synthetic.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least one year after receipt when stored at -20°C.
HANDLING: Protect from light and moisture.

Product Description
Shows anti-carcinogenic, anti-inflammatory and immunomodulatory properties. Suppresses lipopolysaccharide (LPS)-induced nitric oxide (NO) production (IC50=5.5µg/ml). Potent and specific inhibitor of NF-κB and its downstream inflammatory mediators inducible nitric oxide synthase (iNOS; NOS II), prostaglandin E2 (PGE2) and cyclooxygenase-2 (COX-2). Prevents DNA single-strand breaks caused by H2O2.
Product Specific Literature References
Inhibitory effects of caffeic acid ethyl ester on H2O2-induced cytotoxicity and DNA single-strand breaks in Chinese hamster V79 cells: T. Nakayama, et al.; Biosci. Biotechnol. Biochem. 60, 316 (1996) Abstract
Ethyl caffeate suppresses NF-kappaB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin: Y.M. Chiang, et al.; Br. J. Pharmacol. 146, 352 (2005) Abstract
Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines: M. Cardenas, et al.; Bioorg. Med. Chem. 14, 2966 (2006) Abstract
Drastic effect of several caffeic acid derivatives on the induction of heme oxygenase-1 expression revealed by quantitative real-time RT-PCR: K. Suzuki, et al.; Biofactors 28, 151 (2006) Abstract
Related Products
Further Categories Containing This Product:
NF-kB Pathway Inhibitors • Natural Products - Chemopreventive Agents • Natural Products - Nitric Oxide Pathway Modulators • Prostaglandins Other Products • Natural Products - NF-kB Pathway Inhibitors • Natural Products - Immunomodulators
 
 
ALX-380-296 Revised 15-Apr-08 New product
Norfloxacin nicotinate
Add to Clipboard
SYNONYMS 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid nicotinate
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-296-G001   1 g 20.00 USD Add To Cart
ALX-380-296-G005   5 g 50.00 USD Add To Cart
Product Specification
FORMULA: C16H18FN3O3 . C6H5NO2
MW: 319.3 . 123.1
CAS NUMBER: 11803-81-9
PURITY: ≥98% (Assay)
APPEARANCE: White to yellow crystalline solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Fluoroquinolone antibacterial agent. Derivative of norfloxacin (Prod. No. ALX-380-296) with dramatically improved water solubility. Instantly dissociates into norfloxacin and nicotinic acid in the body therefore acting as norfloxacin. Inhibits bacterial DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase). Effective against Gram-negative bacteria; less effective against Gram-positive bacteria.
Product Specific Literature References
Efficacy of norfloxacin nicotinate treatment of broiler breeders against Haemophilus paragallinarum: A. Lublin, et al.; Avian Dis. 37, 673 (1993) Abstract
Norfloxacin nicotinate in the treatment of Pseudomonas aeruginosa infection in the genital tract of a bull: S. Marcus, et al.; Vet. Res. Commun. 18, 331 (1994) Abstract
Tissue distribution and binding to plasma proteins of norfloxacin nicotinate after intramuscular administration in pigs: M. Shem-Tov, et al.; Zentralbl. Veterinarmed. B. 41, 257 (1994) Abstract
Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration: M. Shem-Tov & G. Ziv; Zentralbl. Veterinarmed. B. 41, 60 (1994) Abstract
Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes: S. Soback, et al.; Antimicrob. Agents Chemother. 38, 2336 (1994) Abstract; Full Text
Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys: E. Lavy, et al.; J. Vet. Pharmacol. Ther. 18, 101 (1995) Abstract
Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves: M. Gips & S. Soback; J. Vet. Pharmacol. Ther. 19, 130 (1996) Abstract
Related Products
Further Categories Containing This Product:
Antibiotics - Topoisomerase Inhibitors • Antibiotics - DNA Replication Inhibitors
 
 
ALX-270-444 Revised 07-Apr-08 New product
ABT-888
Add to Clipboard
SYNONYMS 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide . dihydrochloride
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY PARP Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-444-M001   1 mg 50.00 USD Add To Cart
ALX-270-444-M005   5 mg 150.00 USD Add To Cart
Product Specification
FORMULA: C13H16N4O . 2HCl
MW: 244.3 . 73.0
CAS NUMBER: 912445-05-7
PURITY: ≥98% (HPLC)
APPEARANCE: Colorless to white crystalline solid.
SOLUBILITY: Soluble in water or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
IDENTITY: Identity determined by 1H-NMR.

Product Description

Potent inhibitor of PARP-1 and PARP-2 (potency ≤5nM in vitro). Does not inhibit other NAD-binding enzymes. Has minimal CYP450 inhibition and induction. Shows broad spectrum of chemo- and radiopotentiation. Enantiomeric purity ≥97% suitable for in vivo studies. Does not show inherent cytotoxicity and shows no single agent activity in tumor models. Has excellent bioavailability and good blood-brain permeation. Increases tumor growth delay resulting from radiation and DNA-damaging agents.
Product Specific Literature References
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models: J.M. Albert, et al.; Clin. Cancer Res. 13, 3033 (2007) Abstract
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models: C.K. Donawho, et al.; Clin. Cancer Res. 13, 2728 (2007) Abstract
 
 
ALX-270-485 Revised 07-Apr-08 New product
B2
Add to Clipboard
SYNONYMS CPNQ
5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY Sirtuins/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-485-MC05   0.5 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C20H17ClN4O3
MW: 396.8
CAS NUMBER: 115687-05-3
PURITY: ≥95%
APPEARANCE: Yellow solid.
SOLUBILITY: Soluble in DMSO (>5mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light and oxygen.
HAZARD: TOXIC.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable inhibitor of sirtuin 2 (SIRT2) (IC50=35μM). Promotes inclusion formation in cellular models of both Huntington’s disease and Parkinson’s disease. Prevents huntingtin-mediated proteasome dysfunction and reduces α-synuclein-mediated toxicity.
Product Specific Literature References
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases: R.A. Bodner, et al.; PNAS 103, 4246 (2006) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Parkinson's Disease Other Products